NOTE: This was a press release from DelveInsight. It looks like the main objective is to look at the potential for investing in companies that are associated with Cystinuria, but there is some great data here, so thought it was work posting.


Cystinuria Market: Industry Analysis, Treatment, Pipeline Drugs and Key Companies By DelveInsight| Bausch Health, Mission Pharmacal, Retrophin, Advicenne and Many Others

06-27-2022 08:09 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Cystinuria Market

Cystinuria is an inherited metabolic disorder characterized by the abnormal movement (transport) in the intestines and kidneys, of certain organic chemical compounds (amino acids). These include cystine, lysine, arginine, and ornithine. Excessive amounts of undissolved cysteine in the urine (cystinuria) cause the formation of stones (calculi) in the kidney, bladder, or ureter.

DelveInsight’s ‘Cystinuria Market Insight, Epidemiology and Market Forecast – 2032’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Cystinuria in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Cystinuria from 2019 to 2032 segmented by seven major markets.

Click here to know more about Cystinuria Market Report:

Some Key Facts of Cystinuria Market:

• As per DelveInsight estimates, total cases of Cystinuria in the 7MM was found to be 87,311 in 2020. Among all the countries, the estimates show population of Cystinuria in the United States to be ~33,265 in 2020.

• Among the EU5 countries, Germany had the highest prevalent population of Cystinuria followed by France. On the other hand, Spain had the lowest prevalent population.

• The Cystinuria is found to be more prevalent in females as compared to males. In 2020, there were 17,764 prevalent cases of Cystinuria in females and 15,502 prevalent cases in males in the United States and as per DelveInsight’s analysts assessments, in both the genders same trend is seen in all the countries of 7MM.

• In type specific cases, maximum cases belong to Type B Cystinuria with 47% cases, while in Europe Type A is found to be more prevalent, while in Japan about 85.9% of cases belong to Type B Cystinuria.

Request for Free Sample Report, Click here for Cystinuria Market Report:

Key benefits of the Cystinuria Market Report:

• Cystinuria market report covers a descriptive overview and comprehensive insight of the Cystinuria epidemiology and Cystinuria market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• Cystinuria market report provides insights on the current and emerging therapies.
• Cystinuria market report provides a global historical and forecasted market covering drug outreach in 7MM.
• Cystinuria market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cystinuria market.

“Cystinuria as a cause of 1-2% of stones observed in adults and about 10% of those occurring in children.”

The primary objective of Cystinuria treatment is to reduce the cystine concentration in the urine. The foremost aim of cystinuria treatment is to prevent the formation of the stone. The first line of treatment is high-fluid intake, which prevents the formation of new stones and dissolves the previously formed ones. By increasing the volume of urine, the concentration of cystine in the urine is reduced which prevents cystine from precipitating from the urine and forming stones.
Another strategy that has been attempted for cystinuria treatment is alkalization of the urine. The rationale is that in an alkaline (nonacidic) liquid, cystine tends to stay in solution and there it does no harm. Another approach for cystinuria treatment is the administration of D-penicillamine. D-penicillamine promotes the formation of cystine in a different chemical form (mixed disulfide), which is more soluble in the urine and is excreted easily.

To know more about Cystinuria Treatment Market, click here:

Cystinuria Therapies are:
• Cuprimine (d-penicillamine)
• Tiopronin (Thiola)
• ADV7103
• Bucillamine
• Tolvaptan
• And many others

To know more about Cystinuria Therapies, click here:

Cystinuria Companies Covered:
• Bausch Health
• Mission Pharmacal
• Retrophin
• Advicenne
• Revive Therapeutics
• Otsuka Pharmaceutical
• And Many Others

To get complete analysis of Cystinuria Companies, request for sample page:

Table of contents

1. Key Insights
2. Executive Summary of Cystinuria
3. Competitive Intelligence Analysis for Cystinuria
4. Cystinuria : Market Overview at a Glance
5. Cystinuria : Disease Background and Overview
6. Patient Journey
7. Cystinuria Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Cystinuria Treatment
11. Marketed Products
12. Emerging Therapies
13. Cystinuria: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Cystinuria
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Request for Free Sample Request:

Other Trending Reports:

• Aesthetic Implants Market:

• Onycholysis Market:

• France Healthcare Outlook Report:

• Italy Healthcare Outlook Report:

• Primary Progressive Multiple Sclerosis Ppms Market:

Contact us:
Ankit Nigam

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life science. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

This release was published on openPR.